Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07623200 | A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia | PHASE3 | NOT YET_RECRUITING | 426 | — | — | Jul 31, 2026 | Nov 1, 2030 | Jun 3, 2026 | - | — |
Normalization of platelet and white blood cell (WBC) counts and absence of disease progression as defined in the protocol.
| Arm | Type | Description |
|---|---|---|
| INCA033989 | EXPERIMENTAL | Administered intravenous (IV) in accordance with the protocol-defined requirements. |
| Best Available Therapy (BAT) | EXPERIMENTAL | Best Available Therapy (BAT) will be selected by the investigator. |
| Name | Type | Description |
|---|---|---|
| INCA033989 | DRUG | Administered intravenous (IV) in accordance with the protocol-defined requirements. |
| Best Available Treatment | DRUG | Best Available Therapy (BAT) will be selected by the investigator. |
Inclusion Criteria: * Confirmed diagnosis of high-risk ET. * Presence of mutCALR. * Prior treatment with at least 1 cytoreductive therapy. Exclusion Criteria: * Presence of any hematologic malignancy other than ET. * Major bleeding or thrombosis within the last 3 months prior to study enrollment....
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE3 | Bomedemstat, Hydroxyurea, Anagrelide, Busulfan, Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b |
| Incyte Corporation | INCY | 1 | PHASE1 | INCB057643, Ruxolitinib |